Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses data from a Phase I/II trial (NCT03761108) investigating the BCMAxCD3 bispecific antibody, linvoseltamab, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Richter discusses the dose-response curve of this agent, and how further adjustment of dosage and treatment scheduling could improve efficacy and tolerability. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.